CLOs on the Move

Stealth BioTherapeutics

www.stealthbt.com

 
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.stealthbt.com
  • 275 Grove Street Ste. 3-107
    Newton, MA USA 02466
  • Phone: 617.600.6888

Executives

Name Title Contact Details

Similar Companies

LabCentral

LabCentral provides first-class facility and administrative support, skilled laboratory personnel, a domain-relevant expert speaker series ‒ as well as the other critical services and support that early-stage companies need to begin laboratory operations on day one.

Sensei Biotherapeutics

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Partner Therapeutics

Partner Therapeutics is devoted to developing and commercializing cancer medicines and combination therapies that can make a meaningful difference in the lives of cancer patients.

Arranta Bio

Arranta Bio is delivering on its vision to build the best-in-class microbiome contract development and manufacturing organization (CDMO) through our merger with a 10-year veteran CDMO, Captozyme, and the establishment of a commercial-ready manufacturing facility. We provide manufacturing and development support for live biotherapeutic products (LBPs) targeting gut health and microbiome-related diseases by providing development and manufacturing services that bring effective treatments to the market and patients in need.

Virtual Incision

Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.